Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
AbbVie Biotech Ventures
AddedFeb 13, 2024
UpdatedJun 28, 2026
AbbVie Biotech Ventures

AbbVie Biotech Ventures

Operating

ABVI: A US-based venture capital firm specializing in investments in biotech and pharmaceutical sectors.

Location
Chicago, IL, US
Founded
2009
Firm
Compare
Portfolio
Employees
Website

Investments

Accent Therapeutics
Accent Therapeutics

Total Raised

$178M

Rounds

3

Series C$75MJanuary 2024
Series B$63MApril 2020
Mozart Therapeutics
Mozart Therapeutics

Total Raised

$80M

Rounds

2

Series A$25MJune 2023
Quanta Therapeutics
Quanta Therapeutics

Total Raised

$140.7M

Rounds

4

Series D$50.7MMay 2023
Series C$60MOctober 2021
Jnana Therapeutics
Jnana Therapeutics

Total Raised

$207M

Rounds

3

Series C$107MNovember 2022
Series B$50MAugust 2021
Ambagon Therapeutics
Ambagon Therapeutics

Total Raised

$148M

Rounds

3

Series A$85MJanuary 2022
Nitrase Therapeutics
Nitrase Therapeutics

Total Raised

$45.1M

Rounds

4

Series A$7MNovember 2021
Series A$38MApril 2020
Starday Foods
Starday Foods

Total Raised

$4M

Rounds

2

Seed$4MAugust 2021
Stemson Therapeutics
Stemson Therapeutics

Total Raised

$22.5M

Rounds

2

Series A$15MJuly 2021
Ribon Therapeutics
Ribon Therapeutics

Total Raised

$259M

Rounds

7

Series C$65MJune 2021
Caribou Biosciences
Caribou Biosciences
Public

Total Raised

$317.7M

Rounds

9

Series C$115MMarch 2021
Carisma Therapeutics
Carisma Therapeutics
Public

Total Raised

$151.9M

Rounds

8

Series B$12MMarch 2021
Series B$47MJanuary 2021
Series A$6MAugust 2019
Faze Medicines
Faze Medicines

Total Raised

$81M

Rounds

1

Series A$81MDecember 2020
Palleon Pharmaceuticals
Palleon Pharmaceuticals

Total Raised

$147.6M

Rounds

2

Series B$100MSeptember 2020
Jacobio Pharmaceuticals
Jacobio Pharmaceuticals
Public

Total Raised

$212.2M

Rounds

6

Series UnknownJune 2020
Quench Bio
Quench Bio

Total Raised

$50M

Rounds

2

Series A$50MJanuary 2020
Pact Pharma
Pact Pharma

Total Raised

$200M

Rounds

3

Series C$75MJanuary 2020
Prevail Therapeutics
Prevail Therapeutics
Acquired

Total Raised

$129M

Rounds

4

Series B$50MMarch 2019
Ribometrix
Ribometrix

Total Raised

$45.3M

Rounds

3

Series A$30MNovember 2018
Magnolia Neurosciences
Magnolia Neurosciences

Total Raised

$49.4M

Rounds

2

Series A$31MAugust 2018